Genocea Biosciences Inc. was granted an additional 180 calendar days, or until June 11, 2019, by Nasdaq to regain compliance with the exchange's $1 minimum bid price listing requirement.
Previously, the Cambridge, Mass.-based biopharmaceutical company was given until Dec. 12 to regain compliance for continued listing on Nasdaq.
Genocea became eligible for the extension period after it determined it will not be in compliance by Dec. 12 and submitted an application to transfer its securities from listing on the Nasdaq Global Market to the Nasdaq Capital Market.
As a result, Genocea's common stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market at business open on Dec. 17. The company's common stock will continue to trade under the symbol GNCA.
Genocea Biosciences develops vaccines and immunotherapies to treat infectious diseases and cancer.